U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm Metsera, ...

The takeover battle between Novo Nordisk and Pfizer to land weight-loss drug maker Metsera is a sign of "an accelerating M&A ...

Merck announced that sales of Keytruda topped more than $8 billion for the first time in a quarter, up 10% from the same period a year ago. The pharma giant also narrowed its full-year profit outlook ...

Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study ...

Dow Jones Top Company Headlines at 7 PM ET: Amazon Shares Surge on 13% Revenue Jump, Strong Cloud Sales | Apple ... The e-commerce giant said Amazon Web Services is growing at its fastest rate since ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Pfizer Inc. is threatening legal action at an attempt by Novo Nordisk A/S to scupper its acquisition of Metsera Inc., with an unsolicited $9 billion offer for the anti-obesity specialist. That trumps ...

Novo Nordisk, a leader in weight-loss drugs, is offering $6 billion up front with the potential for later milestone payments ...

The Trump administration has promised to "Make America Healthy Again," and we applaud that goal. Pharmaceutical innovation has saved countless lives, but developing new drugs is risky, costly and time ...